Should I buy or sell AVITA Medical stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVITA Medical in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCEL shares. View RCEL analyst ratings or view top-rated stocks .

What is AVITA Medical's stock price target for 2024?

5 Wall Street analysts have issued twelve-month price objectives for AVITA Medical's stock. Their RCEL share price targets range from $19.00 to $40.00. On average, they predict the company's stock price to reach $26.40 in the next year. This suggests a possible upside of 143.3% from the stock's current price. View analysts price targets for RCEL or view top-rated stocks among Wall Street analysts .

How have RCEL shares performed in 2023?

AVITA Medical's stock was trading at $6.60 at the beginning of the year. Since then, RCEL shares have increased by 64.4% and is now trading at $10.85. View the best growth stocks for 2023 here .

When is AVITA Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our RCEL earnings forecast .

How were AVITA Medical's earnings last quarter?

AVITA Medical, Inc. (NASDAQ:RCEL) announced its earnings results on Monday, November, 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.16. The firm had revenue of $7.02 million for the quarter, compared to the consensus estimate of $6.98 million. AVITA Medical had a negative trailing twelve-month return on equity of 45.82% and a negative net margin of 74.16%. During the same quarter in the previous year, the firm earned ($0.48) earnings per share.

What guidance has AVITA Medical issued on next quarter's earnings?

AVITA Medical issued an update on its FY 2023 earnings guidance on Wednesday, October, 18th. The company provided EPS guidance of for the period. The company issued revenue guidance of $51.00 million-$53.00 million, compared to the consensus revenue estimate of $52.41 million.

What other stocks do shareholders of AVITA Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVITA Medical investors own include NVIDIA (NVDA) , Block (SQ) , Alibaba Group (BABA) , Micron Technology (MU) , Netflix (NFLX) , PayPal (PYPL) , Twilio (TWLO) , AbbVie (ABBV) , Inovio Pharmaceuticals (INO) and Livongo Health (LVGO) .

Who are AVITA Medical's major shareholders?

AVITA Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include EAM Investors LLC (0.98%), Bank of New York Mellon Corp (0.50%), Charles Schwab Investment Management Inc. (0.27%), Assenagon Asset Management S.A. (0.26%), Walleye Capital LLC (0.20%) and Invesco Ltd. (0.13%). Insiders that own company stock include David D O'toole, Donna Shiroma, Michael S Perry, Michael S Perry and Suzanne Crowe . View institutional ownership trends .

AVITA Medical Stock Price, News & Analysis (NASDAQ:RCEL)

$10.85

+0.12 (+1.12%)

(As of 11/27/2023 ET)

Compare

Today's Range: $10.46
▼
$10.98
50-Day Range: $9.29
▼
$14.87
52-Week Range: $6.29
▼
$21.70

Volume: 124,795 shs
Average Volume: 193,875 shs
Market Capitalization: $277.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $26.40

AVITA Medical MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 143.3% Upside
$26.40 Price Target
Short Interest: Healthy
2.36% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.62
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$25,030 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.47) to ($1.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

241st out of 936 stocks

Surgical & Medical Instruments Industry

29th out of 92 stocks

3.5

Analyst's Opinion

Consensus Rating
AVITA Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.40, AVITA Medical has a forecasted upside of 143.3% from its current price of $10.85.
Amount of Analyst Coverage
AVITA Medical has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.36% of the float of AVITA Medical has been sold short.
Short Interest Ratio / Days to Cover
AVITA Medical has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AVITA Medical has recently decreased by 20.31%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
AVITA Medical does not currently pay a dividend.
Dividend Growth
AVITA Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RCEL.

2.6

News and Social Media Coverage

News Sentiment
AVITA Medical has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for AVITA Medical this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added AVITA Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVITA Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,030.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.05% of the stock of AVITA Medical is held by insiders.
Percentage Held by Institutions
Only 29.88% of the stock of AVITA Medical is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AVITA Medical are expected to grow in the coming year, from ($1.47) to ($1.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVITA Medical is -8.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVITA Medical is -8.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AVITA Medical has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AVITA Medical Stock (NASDAQ:RCEL)

AVITA Medical, Inc. operates as a regenerative medicine company in the United States, Australia, Japan, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a platform technology allows for the preparation and delivery of spray-on skin cells to regenerate natural healthy epidermis, as well as to use in the treatment of acute thermal burns in patients eighteen years and older. AVITA Medical, Inc. has a research agreement with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

RCEL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RCEL Stock News Headlines

November 22, 2023 | americanbankingnews.com

AVITA Medical (NASDAQ:RCEL) Receives "Overweight" Rating from Cantor Fitzgerald

November 20, 2023 | msn.com

Avita Medical cuts 2023 commercial revenue guidance on longer hospital approval timelines

November 28, 2023 | DTI Trader (Ad)

Important info on NVDA trade

Today, I’m pulling back the curtain on my all-new Everyday Income project. A way for everyday folks to target a couple hundred bucks or more every single day the markets are open… Without breaking a sweat!

November 11, 2023 | markets.businessinsider.com

Avita Medical Surpasses Expectations: Exploring New Markets and International Expansion with Strong Financial Backing

November 11, 2023 | markets.businessinsider.com

Avita Medical’s Promising Financial Trajectory: A Buy Rating Based on Strong Growth Indicators and Diversifying Revenue Streams

November 9, 2023 | benzinga.com

AVITA Medical: Q3 Earnings Insights

November 9, 2023 | finance.yahoo.com

AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe

October 19, 2023 | finance.yahoo.com

AVITA Medical to Announce Third Quarter 2023 Financial Results

November 28, 2023 | DTI Trader (Ad)

Important info on NVDA trade

October 18, 2023 | markets.businessinsider.com

Avita Medical’s Steady Performance and Positive Future Prospects Prompt Buy Rating: An Analysis

October 18, 2023 | msn.com

Avita Medical reports preliminary commercial revenue of $13.5M

October 18, 2023 | finance.yahoo.com

AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives

September 25, 2023 | finance.yahoo.com

AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma

September 22, 2023 | fool.com

Avita Medical (ASX: AVH)

September 21, 2023 | finance.yahoo.com

AVITA Medical to Present at the Cantor Global Healthcare Conference

September 15, 2023 | finance.yahoo.com

With 49% stake, AVITA Medical, Inc. (ASX:AVH) seems to have captured institutional investors' interest

September 6, 2023 | finance.yahoo.com

AVITA Medical to Participate in Upcoming Investor Conferences

August 27, 2023 | insidermonkey.com

5 Best Cosmetic Surgery and Aesthetics Stocks to Buy

August 23, 2023 | msn.com

Cantor Fitzgerald Reiterates AVITA Medical (RCEL) Overweight Recommendation

August 22, 2023 | markets.businessinsider.com

Expert Ratings for AVITA Medical

August 12, 2023 | finance.yahoo.com

AVITA Medical, Inc. (NASDAQ:RCEL) Q2 2023 Earnings Call Transcript

August 12, 2023 | msn.com

Piper Sandler Maintains AVITA Medical (RCEL) Overweight Recommendation

August 11, 2023 | investing.com

Avita Medical (RCEL) Earnings Dates & Reports

August 10, 2023 | finance.yahoo.com

AVITA Medical Reports Second Quarter Financial Results

August 2, 2023 | msn.com

AVITA Medical (RCEL) Price Target Increased by 14.02% to 26.27

July 28, 2023 | msn.com

B of A Securities Maintains AVITA Medical (RCEL) Buy Recommendation

July 20, 2023 | finance.yahoo.com

AVITA Medical to Announce Second Quarter 2023 Financial Results

See More Headlines

Receive RCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVITA Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 11/27/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RCEL
CUSIP: N/A
CIK: 1762303
Web: www.avitamedical.com
Phone: (833) 462-8482
Fax: N/A
Employees: 126
Year Founded: 2008

Price Target and Rating

Average Stock Price Target: $26.40
High Stock Price Target: $40.00
Low Stock Price Target: $19.00
Potential Upside/Downside: +143.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-26,670,000.00
Net Margins: -74.16%
Pretax Margin: -73.98%
Return on Equity: -45.82%
Return on Assets: -37.60%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.25
Quick Ratio: 5.88

Sales & Book Value

Annual Sales: $34.42 million
Price / Sales: 8.05
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.39 per share
Price / Book: 3.20

Miscellaneous

Outstanding Shares: 25,550,000
Free Float: 25,027,000
Market Cap: $277.22 million
Optionable: Not Optionable
Beta: 1.54

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. James M. Corbett (Age 65)
CEO, President & Executive Director
Comp: $787.1k
Mr. Andrew Quick (Age 52)
Chief Technology Officer
Comp: $615.86k
Ms. Donna Shiroma (Age 61)
General Counsel & Secretary
Comp: $642.72k
Mr. David O'Toole
Chief Financial Officer
Mr. David Fencil
Senior Vice President of Global Operations
Ms. Jessica Ekeberg
Investor Relations Executive
Ms. Debbie Garner
Senior Vice President of Global Marketing & Strategy
Mr. Rob Hall
Senior Vice President of Human Resources
Mr. Terry Bromley
Senior Vice President of Global Sales
Dr. Niraj Doshi J.D.
P.M.P., Ph.D., Senior Vice President of Product Development & Program Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell AVITA Medical stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVITA Medical in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCEL shares.
View RCEL analyst ratings or view top-rated stocks.
What is AVITA Medical's stock price target for 2024?: 5 Wall Street analysts have issued twelve-month price objectives for AVITA Medical's stock. Their RCEL share price targets range from $19.00 to $40.00. On average, they predict the company's stock price to reach $26.40 in the next year. This suggests a possible upside of 143.3% from the stock's current price.
View analysts price targets for RCEL or view top-rated stocks among Wall Street analysts.
How have RCEL shares performed in 2023?: AVITA Medical's stock was trading at $6.60 at the beginning of the year. Since then, RCEL shares have increased by 64.4% and is now trading at $10.85.
View the best growth stocks for 2023 here.
When is AVITA Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our RCEL earnings forecast.
How were AVITA Medical's earnings last quarter?: AVITA Medical, Inc. (NASDAQ:RCEL) announced its earnings results on Monday, November, 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.16. The firm had revenue of $7.02 million for the quarter, compared to the consensus estimate of $6.98 million. AVITA Medical had a negative trailing twelve-month return on equity of 45.82% and a negative net margin of 74.16%. During the same quarter in the previous year, the firm earned ($0.48) earnings per share.

What guidance has AVITA Medical issued on next quarter's earnings?: AVITA Medical issued an update on its FY 2023 earnings guidance on Wednesday, October, 18th. The company provided EPS guidance of for the period. The company issued revenue guidance of $51.00 million-$53.00 million, compared to the consensus revenue estimate of $52.41 million.
What other stocks do shareholders of AVITA Medical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AVITA Medical investors own include NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), PayPal (PYPL), Twilio (TWLO), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Livongo Health (LVGO).
Who are AVITA Medical's major shareholders?: AVITA Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include EAM Investors LLC (0.98%), Bank of New York Mellon Corp (0.50%), Charles Schwab Investment Management Inc. (0.27%), Assenagon Asset Management S.A. (0.26%), Walleye Capital LLC (0.20%) and Invesco Ltd. (0.13%). Insiders that own company stock include David D O'toole, Donna Shiroma, Michael S Perry, Michael S Perry and Suzanne Crowe.
View institutional ownership trends.
How do I buy shares of AVITA Medical?: Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RCEL) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial